688235 百济神州
已收盘 01-14 15:00:01
资讯
新帖
简况
百济神州(06160.HK)高开逾3%
每日经济新闻 · 01-14 09:36
百济神州(06160.HK)高开逾3%
港股异动 | 百济神州(06160)高开逾3% 宣布百悦达®在中国商业化上市 首批药品将覆盖全国70个城市
智通财经 · 01-14 09:30
港股异动 | 百济神州(06160)高开逾3% 宣布百悦达®在中国商业化上市 首批药品将覆盖全国70个城市
百济神州：伯恩斯坦上调评级至跑赢大市，目标价升至414美元
美股速递 · 01-12 19:21
百济神州：伯恩斯坦上调评级至跑赢大市，目标价升至414美元
每周股票复盘：百济神州（688235）授出693,186股普通股受限制股份单位
证券之星 · 01-11
每周股票复盘：百济神州（688235）授出693,186股普通股受限制股份单位
美股内部交易 | 百济神州于1月9日披露4笔公司内部人交易情况
同花顺iNews · 01-10
美股内部交易 | 百济神州于1月9日披露4笔公司内部人交易情况
百济神州(06160)授出合共5.33万股美国存托股份受限制股份单位
智通财经 · 01-07
百济神州(06160)授出合共5.33万股美国存托股份受限制股份单位
百济神州新型BCL2抑制剂百悦达（索托克拉片）在中国获得上市许可
老虎资讯综合 · 01-06
百济神州新型BCL2抑制剂百悦达（索托克拉片）在中国获得上市许可
百济神州BCL-2抑制剂“索托克拉”获批上市
医药魔方Info · 01-05
百济神州BCL-2抑制剂“索托克拉”获批上市
加拿大卫生部批准Tevimbra®（注射用Tislelizumab）与吉西他滨和顺铂联合用于成人复发性或转移性鼻咽癌的首选治疗
美股速递 · 2025-12-23
加拿大卫生部批准Tevimbra®（注射用Tislelizumab）与吉西他滨和顺铂联合用于成人复发性或转移性鼻咽癌的首选治疗
获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？
时代财经 · 2025-12-22
获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？
双总裁时代的百济神州 还有哪些故事可讲？
国际金融报 · 2025-12-19
双总裁时代的百济神州 还有哪些故事可讲？
百济神州（688235）披露聘任公司高级管理人员公告，12月19日股价上涨0.86%
证券之星 · 2025-12-19
百济神州（688235）披露聘任公司高级管理人员公告，12月19日股价上涨0.86%
63岁吴晓滨离任百济神州总裁，48岁汪来接任
经济观察网 · 2025-12-19
63岁吴晓滨离任百济神州总裁，48岁汪来接任
百济神州：聘任汪来为公司总裁
每日经济新闻 · 2025-12-18
百济神州：聘任汪来为公司总裁
百济神州获得美国FDA快递通道认证，Bgb-B2033用于肝细胞癌治疗
美股速递 · 2025-12-18
百济神州获得美国FDA快递通道认证，Bgb-B2033用于肝细胞癌治疗
午后突发！港股通创新药ETF（520880）跌2.77%创阶段新低，康方生物、百济神州等大权重龙头领跌
新浪基金 · 2025-12-15
午后突发！港股通创新药ETF（520880）跌2.77%创阶段新低，康方生物、百济神州等大权重龙头领跌
19种药品纳入首版商保目录，5款CAR-T疗法集体入围，影响有多大？
澎湃新闻 · 2025-12-07
19种药品纳入首版商保目录，5款CAR-T疗法集体入围，影响有多大？
百济神州两款药品进入2025年商保创新药目录
北京商报 · 2025-12-07
百济神州两款药品进入2025年商保创新药目录
百济神州(06160)授出合共2.13万个受限制股份单位
智通财经 · 2025-12-04
百济神州(06160)授出合共2.13万个受限制股份单位
美国FDA对Sonrotoclax的优先审查批准，用于治疗复发性或难治性套细胞淋巴瘤
美股速递 · 2025-11-26
美国FDA对Sonrotoclax的优先审查批准，用于治疗复发性或难治性套细胞淋巴瘤
加载更多
公司概况
公司名称：
百济神州有限公司
所属行业：
医药制造业
上市日期：
2021-12-15
主营业务：
百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。截至本报告期末，公司及其控股子公司拥有的发明专利包括美国发明专利64个、中国发明专利67个、日本发明专利30个、欧洲发明专利15个及其他国家或地区的发明专利135个。
发行价格：
192.60
{"stockData":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":308,"timestamp":1768374001000,"preClose":310.8,"halted":0,"volume":3653495,"delay":0,"changeRate":-0.009,"floatShares":114999999,"shares":1541000000,"eps":-0.0994,"marketStatus":"已收盘","change":-2.8,"latestTime":"01-14 15:00:01","open":316.1,"high":318.14,"low":302.51,"amount":1135000000,"amplitude":0.0503,"askPrice":308,"askSize":7,"bidPrice":307.98,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-0.0994,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768440600000},"marketStatusCode":5,"adr":0,"adjPreClose":310.8,"symbolType":"stock_kcb","openAndCloseTimeList":[[1768354200000,1768361400000],[1768366800000,1768374000000]],"highLimit":341.88,"lowLimit":279.72,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1540677809,"isCdr":false,"pbRate":16.18,"roa":"--","roe":"4.26%","epsLYR":-3.64,"committee":-0.166667,"marketValue":474529000000,"turnoverRate":0.0318,"status":1,"afterMarket":{"amount":0,"volume":0,"close":308,"buyVolume":0,"sellVolume":200,"time":1768376037558,"indexStatus":"已收盘 01-14 15:30:00","preClose":310.8},"hkstockBrief":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":205,"timestamp":1768378086009,"preClose":204,"halted":0,"volume":5275213,"delay":0,"premium":"-40.49"},"floatMarketCap":35437000000},"requestUrl":"/m/hq/s/688235","defaultTab":"news","newsList":[{"id":"2603576836","title":"百济神州(06160.HK)高开逾3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603576836","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603576836?lang=zh_cn&edition=full","pubTime":"2026-01-14 09:36","pubTimestamp":1768354599,"startTime":"0","endTime":"0","summary":"每经AI快讯，百济神州(06160.HK)高开逾3%，截至发稿涨3.33%，报210.8港元，成交额1678.72万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601143618443468.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601143618443468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0307460666.USD","BK1500","BK4526","BK4139","BK1161","LU1303224171.USD","LU2328871848.SGD","06160","BK0239","LU1719994722.HKD","LU1969619763.USD","688235","LU0588546209.SGD","BK1588","LU1770034418.SGD","ONC","BK4585","BK1583","LU1251922891.USD"],"gpt_icon":0},{"id":"2603652978","title":"港股异动 | 百济神州(06160)高开逾3% 宣布百悦达®在中国商业化上市 首批药品将覆盖全国70个城市","url":"https://stock-news.laohu8.com/highlight/detail?id=2603652978","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603652978?lang=zh_cn&edition=full","pubTime":"2026-01-14 09:30","pubTimestamp":1768354233,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州高开逾3%，截至发稿，涨3.33%，报210.8港元，成交额1678.72万港元。消息面上，1月14日，据百济神州官微消息，公司宣布其自主研发的1类新药新型BCL2抑制剂百悦达已于1月13日启动供应，首批药品将覆盖全国70个城市。研究结果证实，在经治CLL/SLL及R/R MCL患者中，索托克拉显示出具有临床意义的缓解获益，同时整体耐受性与安全性良好。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0307460666.USD","LU0588546209.SGD","BK4526","BK1161","688235","ONC","LU1719994722.HKD","LU2328871848.SGD","BK4585","LU1969619763.USD","BK1583","BK4139","06160","LU1303224171.USD","BK1500","LU1770034418.SGD","BK1588","BK0239","LU1251922891.USD"],"gpt_icon":0},{"id":"1155268538","title":"百济神州：伯恩斯坦上调评级至跑赢大市，目标价升至414美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1155268538","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155268538?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:21","pubTimestamp":1768216910,"startTime":"0","endTime":"0","summary":"伯恩斯坦研究机构宣布，将百济神州的投资评级从\"与大市同步\"提升至\"跑赢大市\"，同时将其目标股价从362美元大幅上调至414美元。这一调整反映了该机构对百济神州未来发展前景的积极预期。\n此次评级上调基于对公司核心业务增长潜力的重新评估，目标价的上调幅度达到14.4%，显示出分析师对该公司价值的认可。伯恩斯坦认为，百济神州在创新药物研发和商业化方面展现出的优势，有望推动其业绩实现超预期表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","BK4526","ONC","BK4139","BK4585","BK0239"],"gpt_icon":0},{"id":"2602533143","title":"每周股票复盘：百济神州（688235）授出693,186股普通股受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2602533143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602533143?lang=zh_cn&edition=full","pubTime":"2026-01-11 01:52","pubTimestamp":1768067531,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，百济神州报收于312.99元，较上周的268.6元上涨16.53%。本周，百济神州1月9日盘中最高价报317.84元。百济神州有限公司截至2025年12月31日，法定注册资本为231,146.38美元，已发行普通股总数为1,425,622,549股，另在上海科创板上市人民币股份115,055,260股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0588546209.SGD","BK1588","BK1500","06160","688235","LU0307460666.USD","BK1161","LU2328871848.SGD","LU1303224171.USD","LU1770034418.SGD","LU1969619763.USD","BK0239","BK1583","LU1719994722.HKD","LU1251922891.USD"],"gpt_icon":0},{"id":"2602307981","title":"美股内部交易 | 百济神州于1月9日披露4笔公司内部人交易情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2602307981","media":"同花顺iNews","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602307981?lang=zh_cn&edition=full","pubTime":"2026-01-10 08:00","pubTimestamp":1768003200,"startTime":"0","endTime":"0","summary":"2026年1月9日， 百济神州（ONC）披露4笔公司内部人交易情况。高管Lee Chan Henry于2026年1月7日卖出664股。【近期内部交易】披露日期职位姓名交易日期买/卖数量每股成交价/美元总金额/美元2 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/usstock/20260110/c673908974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","688235"],"gpt_icon":0},{"id":"2601787308","title":"百济神州(06160)授出合共5.33万股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2601787308","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601787308?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:49","pubTimestamp":1767775792,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年12月31日，董事会及╱或董事会薪酬委员会根据2016期权及激励计划的条款授予155名承授人合共5.33万股美国存托股份受限制股份单位。该等受限制股份单位相当于69.32万股股份，约占本公告之日公司发行股份总数的0.04%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1303224171.USD","BK1588","BK4139","LU0307460666.USD","688235","LU0588546209.SGD","06160","LU1251922891.USD","BK4526","BK1583","LU2328871848.SGD","BK1500","BK4585","BK0239","LU1719994722.HKD","LU1969619763.USD","ONC","BK1161","LU1770034418.SGD"],"gpt_icon":0},{"id":"1170001608","title":"百济神州新型BCL2抑制剂百悦达（索托克拉片）在中国获得上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1170001608","media":"老虎资讯综合","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170001608?lang=zh_cn&edition=full","pubTime":"2026-01-06 19:02","pubTimestamp":1767697320,"startTime":"0","endTime":"0","summary":"1月6日，$百济神州$宣布，其自研的1类新药新型BCL2抑制剂百悦达获得国家药品监督管理局附条件批准，用于治疗既往接受过至少包含布鲁顿酪氨酸激酶抑制剂在内的一种系统治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤成人患者，以及既往接受过至少两种系统性治疗的复发或难治性套细胞淋巴瘤成人患者。基于此次获批，索托克拉将为已接受过BTK抑制剂治疗的CLL/SLL患者带来新的治疗选择，更使其成为国内首款且唯一可用于治疗MCL的BCL2抑制剂。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百济神州新型BCL2抑制剂百悦达（索托克拉片）在中国获得上市许可","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","ONC","LU1303224171.USD","LU2328871848.SGD","BK1583","LU1719994722.HKD","06160","LU1969619763.USD","BK0239","BK1161","LU1251922891.USD","BK1500","BK4139","BK4526","LU0307460666.USD","LU0588546209.SGD","BK1588","688235","LU1770034418.SGD"],"gpt_icon":0},{"id":"2601800005","title":"百济神州BCL-2抑制剂“索托克拉”获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2601800005","media":"医药魔方Info","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601800005?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:19","pubTimestamp":1767608340,"startTime":"0","endTime":"0","summary":"1 月 5日，NMPA 官网显示，百济神州BCL-2抑制剂“索托克拉”两项适应症中国获批上市，适用于治疗既往接受过治疗的慢性淋巴细胞白血病/ 小淋巴细胞淋巴瘤成人患者，以及治疗既往接受过抗CD20治疗和BTKi治疗的套细胞淋巴瘤成人患者。索托克拉是百济神州开发的一款强效、高选择性BCL-2抑制剂，其设计旨在产生更深、更持久的靶点抑制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-01-05/doc-inhfhavn6767115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1969619763.USD","688235","BK1588","ONC","LU1719994722.HKD","BK0239","BK1583","BK4585","BK1500","BK4526","LU1251922891.USD","LU0307460666.USD","BK1161","LU1770034418.SGD","BK4139","06160","LU2328871848.SGD","LU1303224171.USD","LU0588546209.SGD"],"gpt_icon":0},{"id":"1147294652","title":"加拿大卫生部批准Tevimbra®（注射用Tislelizumab）与吉西他滨和顺铂联合用于成人复发性或转移性鼻咽癌的首选治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1147294652","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147294652?lang=zh_cn&edition=full","pubTime":"2025-12-23 21:04","pubTimestamp":1766495093,"startTime":"0","endTime":"0","summary":"加拿大卫生部已批准Tevimbra®（注射用Tislelizumab）与吉西他滨和顺铂联用，作为成人复发性或转移性鼻咽癌的首选治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688235"],"gpt_icon":0},{"id":"2593483856","title":"获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？","url":"https://stock-news.laohu8.com/highlight/detail?id=2593483856","media":"时代财经","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593483856?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:58","pubTimestamp":1766393880,"startTime":"0","endTime":"0","summary":"12月21日晚间，加科思药业（01167.HK）宣布，已就其自主研发的泛KRAS（Pan-KRAS）抑制剂 JAB-23E73与阿斯利康（AZN.US）达成合作协议。根据协议，阿斯利康将获得该产品在中国以外市场的独家 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251222/c673401182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["LU2148510915.USD","LU1064131003.USD","688331","688235","LU2488822045.USD","LU1064130708.USD","688428","BK0239"],"gpt_icon":0},{"id":"2592959471","title":"双总裁时代的百济神州 还有哪些故事可讲？","url":"https://stock-news.laohu8.com/highlight/detail?id=2592959471","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592959471?lang=zh_cn&edition=full","pubTime":"2025-12-19 23:31","pubTimestamp":1766158317,"startTime":"0","endTime":"0","summary":"12月19日，百济神州迎来新的人事调整。百济神州发布公告称，公司董事会同意聘任全球研发负责人汪来博士担任百济神州总裁，全球研发负责人。聘任生效后，汪来将担任百济神州总裁，全球研发负责人职务，负责管理百济神州研发、业务拓展以及业务联盟关系管理等职能。此外，百济神州方面还透露，吴晓滨仍然担任百济神州总裁、首席运营官COO，与汪来并列为双总裁。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512193597095415.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512193597095415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","ONC","LU1251922891.USD","BK1583","LU1969619763.USD","BK4585","LU0588546209.SGD","BK1161","LU1719994722.HKD","BK1500","688235","BK1588","LU2328871848.SGD","LU1770034418.SGD","LU0307460666.USD","LU1303224171.USD","06160","BK4526","BK4139"],"gpt_icon":0},{"id":"2592150459","title":"百济神州（688235）披露聘任公司高级管理人员公告，12月19日股价上涨0.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592150459","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592150459?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:43","pubTimestamp":1766137421,"startTime":"0","endTime":"0","summary":"截至2025年12月19日收盘，百济神州报收于274.0元，较前一交易日上涨0.86%，最新总市值为4221.46亿元。该股当日开盘272.0元，最高274.88元，最低269.79元，成交额达4.9亿元，换手率为1.56%。公司近日发布公告称，2025年12月17日，经公司董事会审议通过，聘任汪来博士担任百济神州有限公司总裁、全球研发负责人，负责管理公司研发、业务拓展及业务联盟关系管理等职能。汪来博士自2011年加入公司，曾任多个研发领导职务，2021年4月起任全球研发负责人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900027078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1588","LU1303224171.USD","LU0307460666.USD","688235","LU1969619763.USD","LU1251922891.USD","06160","LU2328871848.SGD","BK1583","LU0588546209.SGD","LU1770034418.SGD","BK1500","LU1719994722.HKD","BK0239"],"gpt_icon":0},{"id":"2592136978","title":"63岁吴晓滨离任百济神州总裁，48岁汪来接任","url":"https://stock-news.laohu8.com/highlight/detail?id=2592136978","media":"经济观察网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592136978?lang=zh_cn&edition=full","pubTime":"2025-12-19 09:33","pubTimestamp":1766107980,"startTime":"0","endTime":"0","summary":"经济观察报 记者 张铃12月18日晚，百济神州（688235.SH/06160.HK/ONC.US）公告，聘任汪来担任总裁、全球研发负责人，负责管理研发、业务拓展以及业务联盟关系管理等职能。在2026年1月1日生 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20251219/c673339845.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251219/c673339845.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","688235"],"gpt_icon":0},{"id":"2592350908","title":"百济神州：聘任汪来为公司总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2592350908","media":"每日经济新闻","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592350908?lang=zh_cn&edition=full","pubTime":"2025-12-18 19:47","pubTimestamp":1766058420,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月18日，百济神州(688235.SH)公告称，公司董事会同意聘任汪来博士担任公司总裁，全球研发负责人，负责管理公司研发、业务拓展以及业务联盟关系管理等职能。汪来博士自2021年4 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20251218/c673323648.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251218/c673323648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688235","BK0239"],"gpt_icon":0},{"id":"1132003505","title":"百济神州获得美国FDA快递通道认证，Bgb-B2033用于肝细胞癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1132003505","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132003505?lang=zh_cn&edition=full","pubTime":"2025-12-18 19:05","pubTimestamp":1766055925,"startTime":"0","endTime":"0","summary":"百济神州获得美国FDA快递通道认证，Bgb-B2033用于肝细胞癌治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688235"],"gpt_icon":0},{"id":"2591697904","title":"午后突发！港股通创新药ETF（520880）跌2.77%创阶段新低，康方生物、百济神州等大权重龙头领跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2591697904","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591697904?lang=zh_cn&edition=full","pubTime":"2025-12-15 13:39","pubTimestamp":1765777140,"startTime":"0","endTime":"0","summary":"12月15日午后，港股通创新药板块加速下跌，港股通创新药ETF一度跌至2.77%创近5个月新低，龙头股齐挫，康方生物跌超5%，百济神州跌逾6%，中国生物制药、信达生物跌超3%。 阶段新低之际，“抄底”资金或再行动，港股通创新药ETF场内宽幅溢价，显示买盘资金相对强势。 把握港股创新药低吸窗口期，认准同类最大港股通创新药ETF及其场外联接基金，标的指数恒生港股通创新药精选指数具备三大独特优势：","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-15/doc-inhawauf3976382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0540923850.HKD","LU0417516738.SGD","BK4526","LU2778985437.USD","BK1588","09926","688235","BK4585","LU2328871848.SGD","LU0348767384.USD","LU1770034418.SGD","ONC","LU0348784397.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","IE00BPRC5H50.USD","BK4139","BK0239","LU0348827113.USD","LU1961090484.USD","LU2476274308.USD","LU0307460666.USD","BK1500","LU1251922891.USD","LU2399975544.HKD","06160","BK1574","LU0561508036.HKD","LU0348783233.USD","LU0634319403.HKD","LU0348825331.USD","LU1969619763.USD","520880","LU0417516571.SGD","LU1303224171.USD","LU0348735423.USD","BK1583","LU0348766576.USD","LU2488822045.USD","BK1161","LU1720050803.USD","LU1794554557.SGD","LU1719994722.HKD","LU2476274720.SGD","LU0588546209.SGD","LU0417516902.SGD"],"gpt_icon":0},{"id":"2589877119","title":"19种药品纳入首版商保目录，5款CAR-T疗法集体入围，影响有多大？","url":"https://stock-news.laohu8.com/highlight/detail?id=2589877119","media":"澎湃新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589877119?lang=zh_cn&edition=full","pubTime":"2025-12-07 21:37","pubTimestamp":1765114670,"startTime":"0","endTime":"0","summary":"在7日的大会现场，国家医保局相关负责人还为入选商保创新药目录的企业代表颁发了证书。根据此前公布的数据，首版商保创新药目录申报信息共有141份，涉及药品通用名141个，121个通过形式审查，实际参与商保创新药目录价格协商的药品24个。进入商保目录后，公司CAR-T疗法的对外价格还是不变的，但对于保险公司会有一个折扣价格。两款药物均出现在首版目录名单，有望造福更多AD患者。从最终的结果来看，该产品未能进入商保目录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207213959a439684c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207213959a439684c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4022","06160","02161","BK4230","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","688235","ONC","LU1093756168.USD","LU1093756325.SGD","BK4585","BK4588","02196","LU0154236417.USD","NVO","01228","BK4007","BK4599","02171","BK4532"],"gpt_icon":0},{"id":"2589387525","title":"百济神州两款药品进入2025年商保创新药目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589387525","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589387525?lang=zh_cn&edition=full","pubTime":"2025-12-07 13:56","pubTimestamp":1765086982,"startTime":"0","endTime":"0","summary":"【百济神州两款药品进入2025年商保创新药目录】12月7日，《商业健康保险创新药品目录（2025年）》正式发布，18家创新药企业的19款药品成功纳入，其中，百济神州有两款药品成功纳入，包括达妥昔单抗β注射液以及注射用泽尼达妥单抗。百济神州也是唯一一家两款产品进入商保创新药目录的创新药企。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512073584561139.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512073584561139.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1719994722.HKD","LU2328871848.SGD","BK1161","BK1588","LU1303224171.USD","159992","LU0307460666.USD","BK1574","BK4585","LU1770034418.SGD","BK1583","688235","BK4139","BK4526","BK1500","ONC","BK0239","06160","LU1969619763.USD","LU0588546209.SGD","06978","LU1251922891.USD"],"gpt_icon":0},{"id":"2588002521","title":"百济神州(06160)授出合共2.13万个受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2588002521","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588002521?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:53","pubTimestamp":1764838411,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年11月28日，董事会薪酬委员会根据2016期权及激励计划的条款授予147名承授人合共2.13万股美国存托股份受限制股份单位。该等受限制股份单位相当于27.66万股股份，约占本公告之日公司发行股份总数的0.02%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU0588546209.SGD","BK1500","BK4139","LU1303224171.USD","LU1969619763.USD","LU1251922891.USD","LU0307460666.USD","BK1583","BK0239","BK1588","BK1161","688235","BK4526","LU2328871848.SGD","06160","ONC","LU1719994722.HKD","LU1770034418.SGD"],"gpt_icon":0},{"id":"1189770578","title":"美国FDA对Sonrotoclax的优先审查批准，用于治疗复发性或难治性套细胞淋巴瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1189770578","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189770578?lang=zh_cn&edition=full","pubTime":"2025-11-26 19:02","pubTimestamp":1764154944,"startTime":"0","endTime":"0","summary":"美国FDA对Sonrotoclax的优先审查批准，用于治疗复发性或难治性套细胞淋巴瘤","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768427167360,"stockEarnings":[{"period":"1week","weight":0.0002},{"period":"1month","weight":0.1385},{"period":"3month","weight":0.0781},{"period":"6month","weight":0.2332},{"period":"1year","weight":0.7245},{"period":"ytd","weight":0.1467}],"compareEarnings":[{"period":"1week","weight":0.0099},{"period":"1month","weight":0.0667},{"period":"3month","weight":0.0536},{"period":"6month","weight":0.1674},{"period":"1year","weight":0.2731},{"period":"ytd","weight":0.0396}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百济神州有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"36008人(较上一季度增加55.74%)","perCapita":"3195股","listingDate":"2021-12-15","address":"c/oBeOneMedicinesIGmbH,Aeschengraben27,4051Basel,Switzerland","registeredCapital":"15万元","survey":" 百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。截至本报告期末，公司及其控股子公司拥有的发明专利包括美国发明专利64个、中国发明专利67个、日本发明专利30个、欧洲发明专利15个及其他国家或地区的发明专利135个。","listedPrice":192.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,688235,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}